Literature DB >> 28753746

Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer.

Renzo Colombo1, Rodolfo Hurle2, Marco Moschini3, Massimo Freschi4, Piergiuseppe Colombo5, Maurizio Colecchia6, Lucia Ferrari7, Roberta Lucianò4, Giario Conti8, Tiziana Magnani9, Paolo Capogrosso1, Andrea Conti8, Luisa Pasini2, Giusy Burgio1, Giorgio Guazzoni10, Carlo Patriarca7.   

Abstract

BACKGROUND: Decision making in T1 high-grade bladder cancer patients remains a challenging issue in urologic practice.
OBJECTIVE: To assess the feasibility and potential prognostic role of three different substaging systems in specimens from both primary and second transurethral resection (TUR) of the bladder in T1 high-grade bladder cancer patients. DESIGN, SETTING, AND PARTICIPANTS: A total of 250 consecutive, confirmed pure transitional T1 high-grade bladder tumors submitted to second TUR entered the retrospective study. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Feasibility of two already clinically tested microstaging systems (anatomy-based T1a/T1b/T1c and micrometric T1m/T1e with 0.5-mm thresholds of invasion) and that of a micrometric substage designed by the authors and based on a 1-mm threshold of invasion (Rete Oncologica Lombarda [ROL] system) was assessed by five independent uropathologists on both first and second TUR specimens. Univariable Cox proportional hazards models were attempted to identify significant independent predictors of recurrence and progression after TUR. Kaplan-Meier curves were plotted to compare different substaging methods analyzing recurrence and progression. RESULTS AND LIMITATIONS: The ROL system proved to be feasible in nearly all cases at both first and second TUR. Median follow-up was 60 mo. The univariate Cox regression analysis documented the ROL substage (ROL2 vs ROL1) to be the only statistically significant predictor of progression (hazard ratio: 2.01; 95% CI, 1.03-3.79; p<0.03). For the first time to our knowledge, the substage was investigated and used to assess T1 tumors found at second TUR, registering a high rate of feasibility.
CONCLUSIONS: T1 microstaging using different procedures is feasible on both primary- and second-TUR specimens. A high rate of feasibility may be expected for T1m/T1e and ROL systems. The clinical role of microstaging on second TUR remains to be defined. PATIENT
SUMMARY: The Rete Oncologica Lombarda system showed feasible results in T1 high-grade bladder tumors. Our substratification was predictive of progression of disease.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Grade; Non–muscle-invasive bladder cancer; Progression; Recurrence; Stage; Substaging system

Mesh:

Year:  2016        PMID: 28753746     DOI: 10.1016/j.euf.2016.06.004

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN: 2405-4569


  6 in total

1.  En bloc resection improves the identification of muscularis mucosae in non-muscle invasive bladder cancer.

Authors:  Hua Liang; Tao Yang; Kaijie Wu; Dalin He; Jinhai Fan
Journal:  World J Urol       Date:  2019-03-04       Impact factor: 4.226

2.  Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration.

Authors:  Chiara Lonati; Luca Afferi; Andrea Mari; Andrea Minervini; Wojciech Krajewski; Marco Borghesi; Gerald B Schulz; Michael Rink; Francesco Montorsi; Alberto Briganti; Renzo Colombo; Alberto Martini; Andrea Necchi; Roberto Contieri; Rodolfo Hurle; Paolo Umari; Stefania Zamboni; Claudio Simeone; Francesco Soria; Giancarlo Marra; Paolo Gontero; Jeremy Yuen-Chun Teoh; Tobias Klatte; Anne-Sophie Bajeot; Mathieu Roumiguié; Morgan Rouprêt; Alexandra Masson-Lecomte; Ekaterina Laukhtina; Anne Sophie Valiquette; M Carmen Mir; Alessandro Antonelli; Sarah M H Einerhand; Kees Hendricksen; Roberto Carando; Christian D Fankhauser; Philipp Baumeister; Agostino Mattei; Shahrokh F Shariat; Marco Moschini
Journal:  World J Urol       Date:  2022-02-26       Impact factor: 4.226

3.  Intratumoral Switch of Molecular Phenotype and Overall Survival in Muscle Invasive Bladder Cancer.

Authors:  Camilla De Carlo; Marina Valeri; Noemi Rudini; Paolo Andrea Zucali; Miriam Cieri; Grazia Maria Elefante; Federica D'antonio; Rodolfo Hurle; Laura Giordano; Alessandra Bressan; Massimo Lazzeri; Matteo Perrino; Giorgio Guazzoni; Luigi Maria Terracciano; Piergiuseppe Colombo
Journal:  Cancers (Basel)       Date:  2022-07-02       Impact factor: 6.575

4.  Application of nomograms in the prediction of overall survival and cancer-specific survival in patients with T1 high-grade bladder cancer.

Authors:  Fucai Tang; Zhaohui He; Zechao Lu; Weijia Wu; Yiwen Chen; Genggeng Wei; Yangzhou Liu
Journal:  Exp Ther Med       Date:  2019-09-06       Impact factor: 2.447

5.  Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis.

Authors:  Mehdi Kardoust Parizi; Dmitry Enikeev; Petr V Glybochko; Veronika Seebacher; Florian Janisch; Harun Fajkovic; Piotr L Chłosta; Shahrokh F Shariat
Journal:  World J Urol       Date:  2019-09-06       Impact factor: 4.226

6.  Long-term Follow-up After En Bloc Transurethral Resection of Non-muscle-invasive Bladder Cancer: Results from a Single-center Experience.

Authors:  Marco Paciotti; Paolo Casale; Piergiuseppe Colombo; Vittorio Fasulo; Alberto Saita; Giovanni Lughezzani; Roberto Contieri; Nicolò Maria Buffi; Massimo Lazzeri; Giorgio Guazzoni; Rodolfo Hurle
Journal:  Eur Urol Open Sci       Date:  2021-02-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.